

DELEGATURA PROPIEDAD INDUSTRIAL
MODIFICACIONES Y/O CORRECCIONES A SOLICITUDES EN TRÁMITE

1. TIPO DE SOLICITUD ☐ MODIFICACION ☒ CORRECCION

1.1 IDENTIFICACION DEL TRÁMITE

- ☒ Patente de Invención / PCT/EP2017/082290 - **EXP. NC2019/0005924**
- ☐ Patente de Modelo de utilidad / PCT
- ☐ Diseño Industrial
- ☐ Esquema de Trazado de Circuito

2. DATOS DEL SOLICITANTE ☐ PERSONA NATURAL ☒ PERSONA JURÍDICA

Nombre o Denominación / Nombre Social

ZEALAND PHARMA A/S

Nombre del Representante

Tipo de Empresa: ☐ Micro ☐ Pequeña ☐ Mediana ☐ Otra

Documento de Identificación: ☐ C.C. ☐ C.E. ☐ NIT ☐ NUPI ☐ Otro

Número Identificación:

Nacionalidad/ País de Constitución:

Dirección

DINAMARCA

Smedeland 36 DK-2600 Glostrup (DK)

Dirección electrónica

No. Fax

Número telefónico

mde@mdelaw.com

2442496

2444096

3. DATOS DEL APODERADO

Apellidos y Nombre

Documento de identificación

Tarjeta profesional

DELGADO VILLEGAS, CLEMENCIA

C.C. 51.663.741

T.P. 43.307

Dirección del Representante

Avenida Carrera 24 No. 37-31 OF. 202

Dirección electrónica

No. Fax

Número telefónico

info1@mdelaw.com

2444096

Número de Radicación o Protocolo de poder general:

4.

MODIFICACION Y/O CORRECCIÓN SOLICITADA

☐ Capítulo descriptivo

☒ CORRECIÓN LISTADO DE SECUENCIAS (Ver anexo)

☐ Modificación a los dibujos

5.

MODIFICACION Y/O CORRECCIÓN SOLICITADA

☐ Cesión / cambio solicitante

☐ Cambio de nombre

☐ Cambio de domicilio

☐ Cambio de dirección

☐ Nombre inventor

☐ Momento publicación

☐ Otra :

Especifique

Aparece:

Debe ser:

Nacionalidad/ País de Constitución:	Dirección del solicitante	
Dirección electrónica	No. Fax	Número telefónico

6.

ANEXOS

☒ Comprobante de pago de la tasa para la presentación de la solicitud(es)

No.

Fecha:

☒ Documentos que contienen las modificaciones o correcciones.

☒ Poder, si fuere el caso con el que se acredita la representación.

☐ Copia de la solicitud con sus anexos en medio magnético.


7.

FIRMA (S)

CLEMENCIA DELGADO VILLEGAS

Nombre de la Firmante

C.C.: 51.663.741



Firma

43.307

Tarjeta Profesional

ANEXO

En la lista de secuencias presentada, se ha corregido un error en la presentación de la SEC ID N° 7. La SEQ ID NO. 7 refleja la fórmula general V, que está presente en la página 7, línea 21 de la solicitud PCT presentada. la SEQ ID NO. 7 se ha corregido para alinearla con la fórmula general V, por lo tanto, se ha modificado para incluir un "Xaa" (un residuo de K, k (D-lys), R, Orn, Dap o Dab en el que la cadena lateral se conjuga con un sustituyente) en la posición 16, y se modifica para eliminar el "Xaa" anteriormente en la posición 27.

Esta corrección de la lista de secuencias simplemente representa una presentación formal de la materia revelada directamente en la solicitud tal como se presentó, no se agrega ninguna materia nueva en virtud de la corrección.

P119579CO Sequence listing amended in SEQ 7
SEQUENCE LISTING

<110> Zealand Pharma A/S

<120> ACYLATED GLP-1/GLP-2 DUAL AGONISTS

<130> GRF/FP7327588

<140> PCT/EP2017/082290

<141> 2017-12-11

<150> DK PA201600757

<151> 2016-12-09

<160> 189

<170> PatentIn version 3.5

<210> 1

<211> 33

<212> PRT

<213> Homo sapiens glucagon-like peptide (GLP-2)

<400> 1

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn
1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr
20 25 30

Asp

<210> 2

<211> 31

<212> PRT

<213> Homo sapiens glucagon-like peptide (GLP-1)

<400> 2

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
1 5 10 15

Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly
20 25 30

<210> 3

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-1 dual agonist peptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is Aib or G

<220>

<221> MISC_FEATURE

P119579CO Sequence listing amended in SEQ 7

```

<222> (5)..(5)
<223> Xaa is T or S

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is T or S

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Xaa is S, E or D

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa is L, M, V or a residue of K, k (D-lys), R, Orn, Dap or Dab
in which the side chain is conjugated to a substituent

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> Xaa is A, N or S

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> Xaa is D or E

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is G, E, A or a residue of K, k (D-lys), R, Orn, Dap or Dab
in which the side chain is conjugated to a substituent

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is Q, E, K, L or a residue of K, k (D-lys), R, Orn, Dap or
Dab in which the side chain is conjugated to a substituent

<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> Xaa is A, V or S

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa is R, K or a residue of K, k (D-lys), R, Orn, Dap or Dab in
which the side chain is conjugated to a substituent

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Xaa is D, L or E

<220>
<221> MISC_FEATURE
<222> (24)..(24)
<223> Xaa is A, N or S

<220>
<221> MISC_FEATURE
<222> (27)..(27)
<223> Xaa is I, Q, K, H or Y

<220>

```

P119579C0 Sequence listing amended in SEQ 7

<221> MISC_FEATURE
<222> (28)..(28)
<223> Xaa is Q, E, A, H, Y, L, K, R or S

<220>
<221> MISC_FEATURE
<222> (29)..(29)
<223> Xaa is H, Y, K or Q

<220>
<221> MISC_FEATURE
<222> (33)..(33)
<223> Xaa is D or E

<400> 3

His Xaa Glu Gly Xaa Phe Xaa Xaa Glu Xaa Xaa Thr Ile Leu Xaa Xaa
1 5 10 15

Xaa Ala Xaa Xaa Xaa Phe Ile Xaa Trp Leu Xaa Xaa Xaa Lys Ile Thr
20 25 30

Xaa

<210> 4
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is Aib or G

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is T or S

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa is T or S

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is G or a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is Q, E, K, L or a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Xaa is D or L

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (28)..(28)
 <223> Xaa is Q, E, A, H, Y, L, K, R or S

<220>
 <221> MISC_FEATURE
 <222> (29)..(29)
 <223> Xaa is H, Y or Q

<400> 4

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Xaa Ala Ala Arg Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr
 20 25 30

Asp

<210> 5
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa is T or S with at least one of Xaa at position 5 or 7 being
 a T

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Xaa is T or S with at least one of Xaa at position 5 or 7 being
 a T

<220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> Xaa is L or a residue of K, k (D-lys), R, Orn, Dap or Dab in
 which the side chain is conjugated to a substituent

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is G, E, A or a residue of K, k (D-lys), R, Orn, Dap or Dab
 in which the side chain is conjugated to a substituent

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa is Q, E, K, L or a residue of K, k (D-lys), R, Orn, Dap or
 Dab in which the side chain is conjugated to a substituent

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is R or a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<220>
 <221> MISC_FEATURE
 <222> (21)..(21)
 <223> Xaa is D or L

<220>
 <221> MISC_FEATURE
 <222> (28)..(28)
 <223> Xaa is E, A or Q

<220>
 <221> MISC_FEATURE
 <222> (29)..(29)
 <223> Xaa is H, Y or Q

<400> 5

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Xaa Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Xaa Ala Ala Xaa Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr
 20 25 30

Asp

<210> 6
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa is T or S with at least one of Xaa at position 5 or 7 being a T

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Xaa is T or S with at least one of Xaa at position 5 or 7 being a T

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is G or a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa is E, K, L or a residue of K, k (D-lys), R, Orn, Dap or Dab
 in which the side chain is conjugated to a substituent

<220>
 <221> MISC_FEATURE
 <222> (21)..(21)
 <223> Xaa is D or L

<220>
 <221> MISC_FEATURE
 <222> (28)..(28)
 <223> Xaa is E or A

<220>
 <221> MISC_FEATURE
 <222> (29)..(29)
 <223> Xaa is H, Y or Q

<400> 6

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Xaa Ala Ala Arg Xaa Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr
 20 25 30

Asp

<210> 7
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> Xaa is T or S where at least one of Xaa at position 5 or 7 is a T

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> Xaa is T or S where at least one of Xaa at position 5 or 7 is a T

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent

<220>
 <221> MISC_FEATURE
 <222> (28)..(28)

P119579CO Sequence listing amended in SEQ 7

<223> Xaa is Q, E, A, H, Y, L, K, R or S, e.g. Q, E, A, H, Y or L

<220>

<221> MISC_FEATURE

<222> (29)..(29)

<223> Xaa is H, Y or Q

<400> 7

His Xaa Glu Gly Xaa Phe Xaa Ser Glu Leu Ala Thr Ile Leu Asp Xaa Gln
1 5 10 15

Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Xaa Xaa Lys Ile Thr Asp
20 25 30

<210> 8

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (1)..(1)

<223> Xaa is isoGlu

<400> 8

Xaa Lys Glu Lys
1

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa is [17-Carboxy-heptadecanoyl]-isoGlu

<400> 9

Lys Xaa Lys Glu Lys
1 5

<210> 10

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MISC_FEATURE

P119579C0 Sequence listing amended in SEQ 7

<222> (2)..(2)
 <223> Xaa is [19-Carboxy-nonadecanoyl]-isoGlu

<400> 10

Lys Xaa Lys Glu Lys
 1 5

<210> 11
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<400> 11

Glu Lys Glu Lys Glu Lys
 1 5

<210> 12
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is D-lys

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa is D-lys

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> Xaa is D-lys

<400> 12

Glu Xaa Glu Xaa Glu Xaa
 1 5

<210> 13
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<400> 13

Ala Lys Ala Ala Glu Lys
 1 5

<210> 14

P119579CO Sequence listing amended in SEQ 7

<211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<400> 14

Ala Lys Glu Lys Glu Lys
 1 5

<210> 15
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<400> 15

Ala Thr Ile Leu Glu Lys
 1 5

<210> 16
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent

<400> 16

Glu Lys Glu Lys Glu Xaa
 1 5

<210> 17
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa is D-lys

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa is D-lys

<220>

P119579CO Sequence listing amended in SEQ 7

<221> MISC_FEATURE
 <222> (6)..(6)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 17

Glu Xaa Glu Xaa Glu Xaa
 1 5

<210> 18
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 18

Ala Lys Ala Ala Glu Xaa
 1 5

<210> 19
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 19

Ala Lys Glu Lys Glu Xaa
 1 5

<210> 20
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

P119579CO Sequence listing amended in SEQ 7

<400> 20

Ala Thr Ile Leu Glu Xaa
1 5

<210> 21

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 21

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 22

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 22

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 23
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 23

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 24
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 24

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

```

<210> 25
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
      side chain is conjugated to a substituent

<400> 25
His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1      5      10      15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
      20      25      30

```

Asp

```

<210> 26
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
      side chain is conjugated to a substituent

<400> 26
His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1      5      10      15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
      20      25      30

```

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 27
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 27

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 28
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 28

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 29
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 29

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 30
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 30

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 31
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 31

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 32
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 32

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 33
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 33

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 34
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 34

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 35
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 35

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 36
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 36

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 37
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 37

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

Asp

<210> 38
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 38

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 39
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 39

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

Asp

<210> 40
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 40

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 41
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 41

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 42
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 42

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 43
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 43

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 44
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 44

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 45
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 45

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 46
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 46

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 47
 <211> 33
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide

 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent

 <400> 47

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr
 20 25 30

Asp

<210> 48
 <211> 33
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide

 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent

 <400> 48

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 49
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 49

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr
 20 25 30

Asp

<210> 50
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 50

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 51
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 51

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr
 20 25 30

Asp

<210> 52
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 52

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 53
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 53

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr
 20 25 30

Asp

<210> 54
 <211> 33
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide
 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib
 <220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the
 side chain is conjugated to a substituent
 <400> 54

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 55
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 55

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr
 20 25 30

Asp

<210> 56
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 56

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr
 20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 57
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 57

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa
 1 5 10 15

Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr
 20 25 30

Glu

<210> 58
 <211> 39
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (34)..(38)
 <223> Xaa at positions 34-38 is D-Lys

<220>
 <221> MISC_FEATURE
 <222> (39)..(39)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 58

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu

1 P119579CO Sequence listing amended in SEQ 7
5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa
35

<210> 59
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (34)..(38)
<223> Xaa at positions 34-38 is D-Lys

<220>
<221> MISC_FEATURE
<222> (39)..(39)
<223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 59

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa
35

<210> 60
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (34)..(38)
<223> Xaa at positions 34-38 is D-Lys

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (39)..(39)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 60

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa
 35

<210> 61
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 61

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 62
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579C0 Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 62

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 63
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 63

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 64
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579C0 Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 64

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 65
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 65

His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 66
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579C0 Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 66

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 67
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is a residue of K, k (D-lys), R, Orn, Dap or Dab in which the side chain is conjugated to a substituent

<400> 67

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala
 1 5 10 15

Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 68
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 68

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 69
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 69

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 70
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 70

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 71
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 71

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 72
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 72

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 73
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 73

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 74
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579C0 Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 74

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 75
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 75

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 76
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 76

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly
 1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 77
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> misc_feature
 <222> (16)..(16)
 <223> Xaa can be any naturally occurring amino acid

<220>
 <221> MISC_FEATURE
 <222> (17)..(17)
 <223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 77

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 78
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 78

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 79
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 79

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 80
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 80

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 81
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 81

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 82
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 82

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 83
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 83

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 84
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 84

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

Asp

<210> 85
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 85

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

Asp

<210> 86
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 86

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

Asp

<210> 87
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 87

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 88
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 88

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 89
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue respectively in which the side
 chain is conjugated to the substituent Z1- or Z1Z2

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa indicates an L-lysine residue in which the side chain is
 conjugated to the substituent Z1- or Z1Z2

<400> 89

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 90
 <211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 90

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp

<210> 91
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 91

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 92
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 92

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 93
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 93

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr
20 25 30

Asp

<210> 94
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 94

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr
20 25 30

Asp

<210> 95
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 95

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr
20 25 30

Asp

<210> 96
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 96

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr
20 25 30

Asp

<210> 97
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 97

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr
20 25 30

Asp

<210> 98
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 98

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr
20 25 30

Asp

<210> 99
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 99

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr
20 25 30

Asp

<210> 100
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 100

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr
20 25 30

Asp

<210> 101
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 101

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr
20 25 30

Asp

<210> 102
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 102

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr
20 25 30

Asp

<210> 103
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 103

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr
20 25 30

Asp

<210> 104
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa indicates an L-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 104

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa
1 5 10 15

Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr
20 25 30

Glu

<210> 105
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (34)..(38)
<223> Xaa at positions 34-38 is D-Lys

<220>
<221> MISC_FEATURE
<222> (39)..(39)
<223> Xaa indicates an D-lysine residue in which the side chain is conjugated to the substituent Z1- or Z1Z2

<400> 105

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa

P119579CO Sequence listing amended in SEQ 7

35

<210> 106
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (34)..(38)
<223> Xaa at positions 34-38 is D-Lys

<220>
<221> MISC_FEATURE
<222> (39)..(39)
<223> Xaa indicates an D-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 106

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa
35

<210> 107
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (34)..(38)
<223> Xaa at positions 34-38 is D-Lys

<220>
<221> MISC_FEATURE
<222> (39)..(39)
<223> Xaa indicates an D-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 107

P119579CO Sequence listing amended in SEQ 7

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa
35

<210> 108
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 108

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 109
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 109

P119579CO Sequence listing amended in SEQ 7

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 110
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 110

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 111
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 111

P119579CO Sequence listing amended in SEQ 7

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 112
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 112

His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 113
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 113

P119579CO Sequence listing amended in SEQ 7

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 114
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa indicates an L-lysine residue in which the side chain is
conjugated to the substituent Z1- or Z1Z2

<400> 114

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala
1 5 10 15

Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 115
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 115

P119579CO Sequence listing amended in SEQ 7

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 116
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 116

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 117
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 117

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

P119579CO Sequence listing amended in SEQ 7

Glu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 118
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 118

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 119
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 119

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

P119579CO Sequence listing amended in SEQ 7

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 120
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 120

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 121
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 121

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Gly
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 122
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 122

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 123
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 123

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Gly
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

P119579CO Sequence listing amended in SEQ 7

Asp

<210> 124
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 124

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 125
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 125

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

P119579CO Sequence listing amended in SEQ 7

<210> 126
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 126

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 127
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 127

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

P119579CO Sequence listing amended in SEQ 7

<210> 128
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 128

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp

<210> 129
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 129

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Leu Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp

<210> 130
<211> 33

P119579CO Sequence listing amended in SEQ 7

<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 130

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Glu Ala Ala Arg Leu Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 131
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 131

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 132
<211> 33
<212> PRT
<213> Artificial Sequence

P119579CO Sequence listing amended in SEQ 7

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 132

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 133
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 133

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 134
<211> 33
<212> PRT
<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 134

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 135

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 135

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
20 25 30

Asp

<210> 136

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 136

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 137
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 137

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 138
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>

P119579C0 Sequence listing amended in SEQ 7

<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 138

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 139
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 139

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 140
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)

P119579C0 Sequence listing amended in SEQ 7

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 140

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile His His Lys Ile Thr
20 25 30

Asp

<210> 141

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 141

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Tyr His Lys Ile Thr
20 25 30

Asp

<210> 142

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

P119579CO Sequence listing amended in SEQ 7

```

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 142

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1          5          10          15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Leu His Lys Ile Thr
          20          25          30

```

Asp

```

<210> 143
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

```

```

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 143

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1          5          10          15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Lys His Lys Ile Thr
          20          25          30

```

Asp

```

<210> 144
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

```

```

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE

```

P119579CO Sequence listing amended in SEQ 7

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 144

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Arg His Lys Ile Thr
20 25 30

Asp

<210> 145

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> misc

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 145

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ser His Lys Ile Thr
20 25 30

Asp

<210> 146

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([Hexadecanoyl]- betaAla)

P119579CO Sequence listing amended in SEQ 7

<400> 146

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Gln Gln His Lys Ile Thr
20 25 30

Asp

<210> 147

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]iso-Glu-Peg3)

<400> 147

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Tyr Gln His Lys Ile Thr
20 25 30

Asp

<210> 148

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400> 148

P119579CO Sequence listing amended in SEQ 7

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Lys Gln His Lys Ile Thr
20 25 30

Asp

<210> 149
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([19-carboxy-nonadecanoyl]iso-Lys-Peg3-Peg3-Peg3)

<400> 149

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Gln Lys Ile Thr
20 25 30

Asp

<210> 150
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K(Octadecanoyl)

<400> 150

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
Página 75

1 P119579CO Sequence listing amended in SEQ 7
5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln Tyr Lys Ile Thr
20 25 30

Asp

<210> 151
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K(Hexadecanoyl-isoGlu)

<400> 151

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ser Thr Ile Leu Glu Xaa
1 5 10 15

Gln Ala Ser Arg Glu Phe Ile Ala Trp Leu Ile Ala Tyr Lys Ile Thr
20 25 30

Glu

<210> 152
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> misc_feature
<222> (34)..(34)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> MISC_FEATURE
<222> (35)..(39)
<223> Xaa at positions 35-39 is D-Lys

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (40)..(40)
 <223> Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)
 <400> 152
 His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40

<210> 153
 <211> 40
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (34)..(39)
 <223> Xaa at positions 34-39 is D-Lys

<220>
 <221> MISC_FEATURE
 <222> (40)..(40)
 <223> Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)

<400> 153
 His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 35 40

<210> 154
 <211> 40
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES

P119579CO Sequence listing amended in SEQ 7

<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (34)..(39)
<223> Xaa at positions 34-39 is D-Lys

<220>
<221> MISC_FEATURE
<222> (40)..(40)
<223> Xaa is ([17-carboxy-Heptadecanoyl]-isoGlu)

<400> 154

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40

<210> 155
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu)

<400> 155

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 156
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (10)..(10)
 <223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400> 156

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 157
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400> 157

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 158
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>

P119579CO Sequence listing amended in SEQ 7

<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400> 158

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 159
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400> 159

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 160
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)

P119579C0 Sequence listing amended in SEQ 7

<223> Aib

<220>

<221> MISC_FEATURE

<222> (20)..(20)

<223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-Peg3)

<400> 160

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 161

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-Peg3)

<400> 161

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 162

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)
 <400> 162
 His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

Asp

<210> 163
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-Carboxy-heptadecanoyl]-isoGlu-KEK-Peg3)
 <400> 163

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 164
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE

P119579CO Sequence listing amended in SEQ 7

<222> (16)..(16)

<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 164

His Xaa Glu Gly Thr Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 165

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK)

<400> 165

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 166

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

P119579CO Sequence listing amended in SEQ 7

<400> 166

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp

<210> 167

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 167

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 168

<211> 33

<212> PRT

<213> Artificial Sequence

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 168

P119579CO Sequence listing amended in SEQ 7

His Xaa Glu Gly Thr Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 169
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400> 169

His Xaa Glu Gly Ser Phe Thr Ser Glu Xaa Ala Thr Ile Leu Asp Glu
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 170
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 170

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
Página 85

P119579CO Sequence listing amended in SEQ 7

1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210>	171
<211>	33
<212>	PRT
<213>	Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

```
<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib
```

```
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)
```

<400> 171

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210>	172
<211>	33
<212>	PRT
<213>	Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>	
<221>	MOD_RES
<222>	(2)..(2)
<223>	Aib

```
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)
```

<400> 172

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

P119579CO Sequence listing amended in SEQ 7

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Ala His Lys Ile Thr
 20 25 30

Asp

<210> 173
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 173

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Lys Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 174
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400> 174

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 Página 87

Asp

<210> 175
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 175

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Glu Gly
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

Asp

<210> 176
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 176

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala
1 5 10 15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
20 25 30

P119579C0 Sequence listing amended in SEQ 7

Asp

```

<210> 177
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400> 177
His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala
1          5          10          15

Xaa Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
          20          25          30

```

Asp

```

<210> 178
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> GLP-1/GLP-2 Dual agonist peptide

<220>
<221> MOD_RES
<222> (2)..(2)
<223> Aib

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 178
His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
1          5          10          15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
          20          25          30

```

Asp

P119579CO Sequence listing amended in SEQ 7

<210> 179
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 179

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 180
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400> 180

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

P119579C0 Sequence listing amended in SEQ 7

<210> 181
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-Peg3)

<400> 181

His Xaa Glu Gly Thr Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Glu
 1 5 10 15

Gln Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 182
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (20)..(20)
 <223> Xaa is K([19-Carboxy-nonadecanoyl]-isoGlu-KEK-Peg3)

<400> 182

His Xaa Glu Gly Ser Phe Thr Ser Glu Leu Ala Thr Ile Leu Asp Ala
 1 5 10 15

Lys Ala Ala Xaa Asp Phe Ile Ala Trp Leu Ile Glu His Lys Ile Thr
 20 25 30

Asp

<210> 183

P119579CO Sequence listing amended in SEQ 7

<211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Xaa is betaAla

<400> 183

Xaa Lys Glu Lys
 1

<210> 184
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Xaa is isoLys

<400> 184

Xaa Lys Glu Lys
 1

<210> 185
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa is isoGlu

<400> 185

Lys Glu Lys Xaa
 1

<210> 186
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> GLP-1/GLP-2 Dual agonist peptide

P119579CO Sequence listing amended in SEQ 7

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa is betaAla

<400> 186

Lys Glu Lys Xaa
 1

<210> 187
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> Xaa is isoLys

<400> 187

Lys Glu Lys Xaa
 1

<210> 188
 <211> 33
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> GLP-1/GLP-2 Dual agonist peptide

<220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> Aib

<220>
 <221> MISC_FEATURE
 <222> (16)..(16)
 <223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 188

His Xaa Asp Gly Ser Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
 1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
 20 25 30

Asp

<210> 189
 <211> 33
 <212> PRT
 <213> Artificial Sequence

P119579CO Sequence listing amended in SEQ 7

<220>

<223> GLP-1/GLP-2 Dual agonist peptide

<220>

<221> MOD_RES

<222> (2)..(2)

<223> Aib

<220>

<221> MISC_FEATURE

<222> (16)..(16)

<223> Xaa is K([17-carboxy-heptadecanoyl]-isoGlu)

<400> 189

His Xaa Glu Gly Ser Phe Ser Ser Glu Leu Ala Thr Ile Leu Asp Xaa
1 5 10 15

Gln Ala Ala Arg Asp Phe Ile Ala Trp Leu Ile Gln His Lys Ile Thr
20 25 30

Asp